B7-1/CD80 蛋白, Cynomolgus (208a.a, HEK293, His)

CD80 is a costimulatory cytokine for cancer immunity that is activated by binding to CD28 or CTLA-4. Tumor immune evasion occurs when CD80 expression is low. The increased expression of CD80 induced by TP53 stimulates anti-tumor immune responses. B7-1/CD80 Protein, Cynomolgus (208a.a, HEK293, His) is the recombinant cynomolgus-derived B7-1/CD80 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of B7-1/CD80 Protein, Cynomolgus (208a.a, HEK293, His) is 208 a.a., with molecular weight of 35-55 kDa.

CD80 是一种膜受体，是免疫细胞限制癌症进展的共刺激细胞因子。CD80 通过结合 CD28 或 CTLA-4 来激活，进而诱导 T 细胞增殖和细胞因子产生。结肠癌的免疫逃逸机制则与 CD80 的低表面表达有关，当肿瘤细胞表面上 CD80 的上调可成功激活抗肿瘤免疫反应。可能由于免疫系统的选择性压力，肿瘤进展过程中经常性失去 CD80 的正常表达水平。TP53 是人类癌细胞中 CD80 表达调节剂，CD80 表达与 TP53 激活具有很强的相关性。TP53 通过在人类癌症上皮细胞中诱导 CD80 诱发抗肿瘤免疫反应。CD80 可作为腺病毒 B 亚型的受体，并可能在狼疮神经病中发挥作用。CD80/CD86 结合的腺病毒血清型 5 (Ad5)/3 嵌合体提高了表达和转导效率，在脑肿瘤中具有优异的转导效率和低毒性。另外，检测尿液 CD80 排泄水平，能够区分足突消失和人类狼疮肾炎的小鼠模型中的微小病变性疾病和局灶节段性肾小球硬化。

Loaded Cynomolgus CTLA-4-Fc on Protein A Biosensor, can bind Cynomolgus B7-1-His with an affinity constant of 0.87 uM as determined in BLI assay.

Cynomolgus

HEK293

C-6*His

G7NXN7 (V35-N242)

102140078  [NCBI]

VATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVMLSVKADFPTPSITDFEIPPSNIRRIICSTSGGFPEPHLSWLENGEELNAISTTVSQDPETELYTVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTPKQEHFPDN

35-55 kDa

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.